Core Viewpoint - The stock of Pagoda Biopharma-B (02565) has risen over 8%, reaching a new high of 52.2 HKD, following the announcement of positive clinical trial results for PB-718 [1] Group 1: Clinical Trial Results - Pagoda Biopharma disclosed results from an Ib/IIa clinical trial for PB-718, showing a significant reduction in liver fat content (MRI-PDFF) after 18 weeks of treatment at a dosage of 1.6 mg, with a mean percentage change of -57.14% from baseline and a maximum reduction of 62% [1] - For comparison, semaglutide in the MASH phase II study showed a reduction of only 46.2% in liver fat content after 24 weeks at a dosage of 2.4 mg [1] Group 2: Future Prospects - The company has indicated that the NDA for PB-119 has been accepted by the National Medical Products Administration, with expectations for commercialization in China soon [1] - Pagoda Biopharma has successfully established a pipeline of six investigational drugs targeting chronic diseases, focusing on the treatment of metabolic diseases and their complications [1] - The company's core strategy emphasizes continuous innovation, with internal assessments indicating that several candidate drugs possess dual value potential as both "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness [1]
港股异动 | 派格生物医药-B(02565)涨超8%破顶 PB-718最新临床数据亮眼 PB-119商业化在即